Implementation of a pharmacogenomics service in a community pharmacy

Journal of the American Pharmacists Association

Volumn 54, Issue 2, 2014, Pages 172-180

  Ferreri, Stefanie P ^a   Greco, Angelo J ^b,c   Michaels, Natasha M ^d   O'Connor, Shanna K ^c,e   Chater, Rebecca W ^f,g   Viera, Anthony J ^h   Faruki, Hawazin ⁱ   McLeod, Howard L ^j,k   Roederer, Mary W ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUQUESNE UNIVERSITY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d Kerr Drug Inc   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Ateb Inc   (United States)

^g Kerr Drug Inc   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ Clinical Diagnostic Strategies   (United States)

^j LABORATORY CORPORATION OF AMERICA   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

Clopidogrel; Community pharmacy; Cytochrome p450 isoenzymes; Personalized medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL PHARMACY; DIABETES EDUCATION; FEASIBILITY STUDY; FEMALE; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH INSURANCE; HOSPITAL DEPARTMENT; HUMAN; IMMUNIZATION; MALE; MEDICATION THERAPY MANAGEMENT; PATIENT PARTICIPATION; PHARMACIST; PHARMACOGENOMICS; PHARMACY; POINT OF CARE TESTING; REIMBURSEMENT; WILD TYPE; ANALOGS AND DERIVATIVES; ECONOMICS; GENETICS; METABOLISM; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PHARMACOGENETICS; PHYSICIAN; PROCEDURES; PROFESSIONAL STANDARD; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COMMUNITY PHARMACY SERVICES; CYTOCHROME P-450 CYP2C19; FEASIBILITY STUDIES; FEMALE; GENETIC TESTING; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; PHARMACISTS; PHARMACOGENETICS; PHYSICIANS; PLATELET AGGREGATION INHIBITORS; PROFESSIONAL ROLE; REIMBURSEMENT MECHANISMS; TICLOPIDINE;

EID: 84898880198     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2014.13033     Document Type: Article

References (33)

1. Table of pharmacogenomic biomarkers in drug labels. Accessed at http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm, February 7, 2013.
2. Grice GR, Seaton TL Woodland AM, McLeod HL. Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics. 2006;7(1):61-65.
3. Freuh FW. Considerations for safety pharmacogenetics in clinical practice. Drug Discov Today. 2011;16(19-20):898-901.
4. Clopidogrel [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2011
5. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
6. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109:3171-3175.
7. Fukuoka T, Furuya D, Takeda H, et al. Evaluation of clopidogrel resistance in ischemic stroke patients. Intern Med. 2011;50:31-35.
8. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
9. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antipltelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
10. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in abcb1 and cyp2c19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in theTRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312-1319.
11. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
12. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-1934. (Pubitemid 351636443)
13. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest. 2008;133(6 suppl):815S-843S.
14. Becker RC, Meade TW, Berger PB. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest. 2008;133(6 Suppl):776S-814S.
15. Mega JL, Simon T, Collet JS, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA. 2010;304(16):1821-1830.
16. Strom CM, Goos D, Crossley B, et al. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med. 2012;14(1):95-100.
17. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e637Se668S.
18. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2):328-332.
19. Giusti B, Gori AM, Marcucci R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007;17(12):1057-1064. (Pubitemid 351339490)
20. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317.
21. Academy of Managed Care Pharmacy. Sound medication therapy management programs. 2006 consensus document. J Manag Care Pharm. 2006;12(3):S1-S15.
22. Padgett L, O'Connor S, Roederer M, et al. Pharmacogenomics in a community pharmacy: ACT now. J Am Pharm Assoc. 2011;51:189-193.
23. Owen J. Integrating pharmacogenomics into pharmacy practice via medication therapy management. J Am Pharm Assoc. 2011;51:e64-e74.
24. Benefit-cost analysis shows strong return on North Carolina health and wellness trust fund investments. Accessed at http://www.healthwellnc.com/ NCHWTFSiteAdmin/Documents/Press-CostBenefitAnalysesRelease.pdf, February 11, 2013.
25. North Carolina Board of Pharmacy. Clinical pharmacist practitioners. Accessed at http://www.ncbop.org/pharmacists-cpp.htm, February 7, 2013.
26. O'Connor SK, Ferreri SP, Michaels NM, et al. Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics. 2012;13(8):955-962.
27. O'Connor SK, Ferreri SP, Michaels NM, et al. Considerations for making pharmacogenetic testing in a community pharmacy a reality. J Am Pharm Assoc. 2012;52:e259-e265.
28. Swen JJ, van der Straaten T, Wessels JA, et al. Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. Eur J Clin Pharmacol. 2012 Apr;68(4):363-370.
29. Michaels NM, Jenkins GF Pruss DL, et al. Retrospective analysis of community pharmacists' recommendations in the North Carolina Medicaid medication therapy management program. J Am Pharm Assoc. 2010;50:347-353.
30. DeName B, Divine H, Nicholas A, et al. Identification of medication-related problems and health care provider acceptance of pharmacist recommendations in the DiabetesCARE program. J Am Pharm Assoc. 2008;48(6):731-736.
31. Doucette WR, McDonough RP, Klepser D, McCarthy R. Comprehensive medication therapy management: identifying and resolving drug-related issues in a community pharmacy. Clin Ther. 2005;27(7):1104-1111. (Pubitemid 41262469)
32. Perera PN, Guy MC, Sweaney AM, Boesen KP. Evaluation of prescriber responses to pharmacist recommendations communicated by fax in a medication therapy management program (MTMP). J Manag Care Pharm. 2011;17(5):345-354.
33. Guill JV, Griffin LA, Goodwin TD. Columbus Air Force Base medication profile intervention practice innovation. J Am Pharm Assoc. 2008;48:654-658.